BRPI0920356A2 - Processo para a preparação de compostos úteis como inibidores de sglt - Google Patents

Processo para a preparação de compostos úteis como inibidores de sglt

Info

Publication number: BRPI0920356A2
Authority: BR; Brazil
Prior art keywords: preparation; compounds useful; sglt inhibitors; sglt; inhibitors
Prior art date: 2008-10-17

Application number

BRPI0920356-7A

Other languages

English (en)

Inventor

Walter Ferdinand Maria Filliers

Mitsuhiro Yada

Christopher Teleha

Rudy Laurent Maria Broeckx

Patrick Hubert J Nieste

Masanori Hatsuda

Masahiko Yoshinaga

Original Assignee

Janssen Pharmaceutica Nv

Mitsubishi Tanabe Pharma Corp

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2008-10-17

Filing date

2009-10-15

Publication date

2015-08-04

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42106967&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0920356(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2009-10-15 Application filed by Janssen Pharmaceutica Nv, Mitsubishi Tanabe Pharma Corp filed Critical Janssen Pharmaceutica Nv

2015-08-04 Publication of BRPI0920356A2 publication Critical patent/BRPI0920356A2/pt

2021-09-21 Publication of BRPI0920356B1 publication Critical patent/BRPI0920356B1/pt

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
- C07D333/12—Radicals substituted by halogen atoms or nitro or nitroso radicals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H13/00—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids
- C07H13/02—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by carboxylic acids
- C07H13/04—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by carboxylic acids having the esterifying carboxyl radicals attached to acyclic carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H7/00—Compounds containing non-saccharide radicals linked to saccharide radicals by a carbon-to-carbon bond
- C07H7/04—Carbocyclic radicals

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
General Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Engineering & Computer Science (AREA)
Molecular Biology (AREA)
Genetics & Genomics (AREA)
Biotechnology (AREA)
Biochemistry (AREA)
Diabetes (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Epidemiology (AREA)
Endocrinology (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Hematology (AREA)
Bioinformatics & Cheminformatics (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Emergency Medicine (AREA)
Obesity (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
Plural Heterocyclic Compounds (AREA)
Saccharide Compounds (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

BRPI0920356-7A 2008-10-17 2009-10-15 Processo para a preparação de compostos úteis como inibidores de sglt BRPI0920356B1 (pt)

Applications Claiming Priority (7)

Application Number	Priority Date	Filing Date	Title
US10626008P	2008-10-17	2008-10-17
US10623108P	2008-10-17	2008-10-17
US61/106,260		2008-10-17
US61/106,231		2008-10-17
US12/578,934		2009-10-14
US12/578,934 US9056850B2 (en)	2008-10-17	2009-10-14	Process for the preparation of compounds useful as inhibitors of SGLT
PCT/EP2009/063503 WO2010043682A2 (en)	2008-10-17	2009-10-15	Process for the preparation of compounds useful as inhibitors of sglt

Publications (2)

Publication Number	Publication Date
BRPI0920356A2 true BRPI0920356A2 (pt)	2015-08-04
BRPI0920356B1 BRPI0920356B1 (pt)	2021-09-21

Family

ID=42106967

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
BRPI0920356-7A BRPI0920356B1 (pt)	2008-10-17	2009-10-15	Processo para a preparação de compostos úteis como inibidores de sglt

Country Status (30)

Country	Link
US (1)	US9056850B2 (pt)
EP (3)	EP2455374B1 (pt)
JP (3)	JP6123111B2 (pt)
KR (2)	KR101724598B1 (pt)
CN (3)	CN102264714A (pt)
AR (1)	AR073892A1 (pt)
AU (1)	AU2009305413B2 (pt)
BR (1)	BRPI0920356B1 (pt)
CA (2)	CA2946212C (pt)
CL (1)	CL2011000849A1 (pt)
CY (3)	CY1113867T1 (pt)
DK (3)	DK2346888T3 (pt)
EA (1)	EA021373B1 (pt)
ES (3)	ES2611881T3 (pt)
HK (1)	HK1224289A1 (pt)
HR (3)	HRP20130254T1 (pt)
HU (2)	HUE052432T2 (pt)
IL (2)	IL212270A0 (pt)
LT (2)	LT2457908T (pt)
MX (1)	MX2011004054A (pt)
NZ (1)	NZ592204A (pt)
PL (3)	PL2346888T3 (pt)
PT (3)	PT2455374T (pt)
RS (3)	RS52740B (pt)
SI (3)	SI2455374T1 (pt)
SM (4)	SMT201700092T1 (pt)
TW (3)	TWI588143B (pt)
UA (1)	UA107450C2 (pt)
WO (1)	WO2010043682A2 (pt)
ZA (1)	ZA201103587B (pt)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP2200606B1 (en) *	2007-09-10	2017-10-25	Janssen Pharmaceutica, N.V.	Process for the preparation of compounds useful as inhibitors of sglt
US9056850B2 (en) *	2008-10-17	2015-06-16	Janssen Pharmaceutica N.V.	Process for the preparation of compounds useful as inhibitors of SGLT
US20110009347A1 (en) *	2009-07-08	2011-01-13	Yin Liang	Combination therapy for the treatment of diabetes
JP5658751B2 (ja)	2009-07-10	2015-01-28	ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプＪａｎｓｓｅｎＰｈａｒｍａｃｅｕｔｉｃａＮａａｍｌｏｚｅＶｅｎｎｏｏｔｓｃｈａｐ	１−（β−Ｄ−グルコピラノシル）−４−メチル−３−［５−（４−フルオロフェニル）−２−チエニルメチル］ベンゼンのための結晶化方法
NZ599306A (en) *	2009-10-14	2014-06-27	Janssen Pharmaceutica Nv	Process for the preparation of compounds useful as inhibitors of sglt2
US8163704B2 (en)	2009-10-20	2012-04-24	Novartis Ag	Glycoside derivatives and uses thereof
CA2799204C (en) *	2010-05-11	2018-11-06	Janssen Pharmaceutica Nv	Pharmaceutical formulations comprising 1 - (beta-d-glucopyranosyl) - 2 -thienylmethylbenzene derivatives as inhibitors of sglt
US20120009259A1 (en) *	2010-07-06	2012-01-12	Urbain Alfons Clementina Delaet	Formulation for co-therapy treatment of diabetes
CA2832938C (en) *	2011-04-13	2019-09-03	Janssen Pharmaceutica Nv	Process for the preparation of compounds useful as inhibitors of sglt2
US9035044B2 (en)	2011-05-09	2015-05-19	Janssen Pharmaceutica Nv	L-proline and citric acid co-crystals of (2S, 3R, 4R, 5S,6R)-2-(3-((5-(4-fluorophenyl)thiopen-2-yl)methyl)4-methylphenyl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol
WO2013152476A1 (en) *	2012-04-10	2013-10-17	Theracos, Inc.	Process for the preparation of benzylbenzene sglt2 inhibitors
US9193751B2 (en)	2012-04-10	2015-11-24	Theracos, Inc.	Process for the preparation of benzylbenzene SGLT2 inhibitors
WO2014180872A1 (en)	2013-05-08	2014-11-13	Lek Pharmaceuticals D.D.	NOVEL CRYSTALLINE HYDRATES OF 1-(ß-D-GLUCOPYRANOSYL)-4-METHYL-3-[5-(4-FLUOROPHENYL)-2-THIENYLMETHYL]BENZENE
CN104418834B (zh) *	2013-08-23	2017-09-15	重庆博腾制药科技股份有限公司	一种抗糖尿病药物中间体的合成方法
CN104418847A (zh) *	2013-09-10	2015-03-18	天津药物研究院	4-(6-脱氧-β-D-吡喃葡萄糖基)-2-[5-(4-氟苯基)噻吩-2-甲基]-1-甲基苯的制备工艺
CN103601715B (zh) *	2013-11-22	2015-08-19	沈阳化工大学	一种2-(4-氟苯基)噻吩的分离提纯方法
EP2918579A1 (en)	2014-03-14	2015-09-16	LEK Pharmaceuticals d.d.	Synthesis of 2-arylmethyl-5-aryl-thiophene
EP2933255A1 (en)	2014-04-17	2015-10-21	LEK Pharmaceuticals d.d.	Novel crystalline form of 1-(beta-D-glucopyranosyl)-4- methyl-3-[5-(4-fluorophenyl)-2-thienylmethyl]benzene
US9695159B2 (en)	2014-05-27	2017-07-04	Glenmark Pharmaceuticals Limited	Process for preparation of canagliflozin
CN105330706B (zh) *	2014-06-05	2019-04-16	江苏豪森药业集团有限公司	卡格列净中间体的制备方法
CN104119324B (zh) *	2014-07-23	2016-03-30	齐鲁天和惠世制药有限公司	一种卡格列净的制备方法
CN104292209A (zh) *	2014-09-11	2015-01-21	浙江丽晶化学有限公司	一种制备2-(4-氟苯基)噻吩(化合物v)的新方法
CN104402946B (zh) *	2014-11-17	2018-01-02	连云港恒运药业有限公司	卡格列净中间体及其无定形的制备方法
WO2016083790A1 (en) *	2014-11-25	2016-06-02	Cipla Limited	Process for the preparation of canagliflozin
CN105753910A (zh) *	2014-12-16	2016-07-13	康普药业股份有限公司	一种卡格列净中间体的制备方法
CN105753827A (zh) *	2014-12-17	2016-07-13	中美华世通生物医药科技（武汉）有限公司	制备化合物的方法
US10508128B2 (en)	2015-02-09	2019-12-17	Indoco Remedies Limited	Process for the preparation of SGLT inhibitor compounds
US10351492B2 (en) *	2015-02-16	2019-07-16	B. G. Negev Technologies And Applications	Introduction of alkyl substituents to aromatic compounds
WO2016135747A2 (en) *	2015-02-27	2016-09-01	Msn Laboratories Private Limited	Process for the preparation of amorphous (1s)-1,5-anhvdro-1-[3-[[5-(4 fluorophennyl)-2-thienyl]methvl]-4-methylphenyl]-d-glucitol and its polymorphs thereof
ES2817526T3 (es)	2015-05-22	2021-04-07	Janssen Pharmaceutica Nv	Forma cristalina anhidra de (1S)-1,5-anhidro-1-[3-[[5-(4-fluorofenil)-2-tienil]metil]-4-metilfenil]-D-glucitol
US20170071970A1 (en)	2015-09-15	2017-03-16	Janssen Pharmaceutica Nv	Co-therapy comprising canagliflozin and phentermine for the treatment of obesity and obesity related disorders
CZ2015729A3 (cs)	2015-10-13	2017-04-26	Zentiva, K.S.	Příprava intermediátů pro syntézu Canagliflozinu a Dapagliflozinu
CN106938998B (zh) *	2017-04-07	2018-07-03	四川智强医药科技开发有限公司	卡格列净有关物质的合成方法
EP3621977A4 (en)	2017-05-09	2021-04-07	Piramal Pharma Limited	SGLT2 INHIBITOR PREPARATION PROCESS AND ITS INTERMEDIARIES
CN109553609B (zh) *	2017-09-26	2020-09-04	北大方正集团有限公司	一种卡格列净的制备方法
US12018007B2 (en)	2018-05-31	2024-06-25	Tokuyama Corporation	Method for manufacturing diarylmethane compound
JP7046868B2 (ja) *	2018-05-31	2022-04-04	株式会社トクヤマ	ジアリールメタン化合物の製造方法
WO2020050361A1 (ja) *	2018-09-06	2020-03-12	株式会社トクヤマ	β－Ｃ－アリールグリコシド誘導体の製造方法
CN109180662A (zh) *	2018-10-17	2019-01-11	北大医药股份有限公司	一种卡格列净的制备方法
TW202039428A (zh) *	2018-12-17	2020-11-01	日商德山股份有限公司	Ｃ－芳基羥基二醇化物（Ｃ－Ａｒｙｌｈｙｄｒｏｘｙｇｌｙｃｏｘｉｄｅ）衍生物之製造方法
JP2022028986A (ja) *	2018-12-17	2022-02-17	株式会社トクヤマ	Ｃ－アリールヒドロキシグリコキシド誘導体の製造方法
CN110698468B (zh) *	2019-09-24	2020-11-03	杭州华东医药集团新药研究院有限公司	一种坎格列净的制备方法
CN111057049B (zh) *	2019-11-18	2021-06-01	杭州华东医药集团新药研究院有限公司	一种卡格列净半水化合物的制备方法
CN113943329A (zh) *	2020-07-16	2022-01-18	尚科生物医药（上海）有限公司	一种坎格列净中间体的非对映异构体的制备方法
US20240025873A1 (en)	2020-11-18	2024-01-25	Tokuyama Corporation	Method for producing ketone derivative
CN112608299A (zh) *	2020-12-24	2021-04-06	山东铂源药业有限公司	一种4-(6-氨基吡啶-3-基)哌啶-1-甲酸叔丁酯的合成方法
CN113372326A (zh) *	2021-06-23	2021-09-10	江苏法安德医药科技有限公司	一种2-(4-氟苯基)噻吩的分离提纯方法
CN113429379A (zh) *	2021-06-28	2021-09-24	江苏法安德医药科技有限公司	一种lh-1801中间体及其制备方法和应用
JPWO2023080243A1 (pt) *	2021-11-08	2023-05-11
CN115557940B (zh) *	2022-12-06	2023-06-20	恒升德康(南京)医药科技有限公司	一种利用微通道反应器连续化生产卡格列净的方法
CN116789716A (zh) *	2023-06-26	2023-09-22	南京科默生物医药有限公司	一种达格列净和艾托格列净中间体的制备方法

Family Cites Families (137)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US2799241A (en)	1949-01-21	1957-07-16	Wisconsin Alumni Res Found	Means for applying coatings to tablets or the like
US4160861A (en)	1977-10-03	1979-07-10	Merck & Co., Inc.	Method for the separation of antibiotic macrolides
US4584369A (en)	1981-07-31	1986-04-22	Sloan-Kettering Institute For Cancer Research	Anti-leukemic beta-glycosyl C-nucleosides
JPS5939889A (ja)	1982-08-30	1984-03-05	Noguchi Kenkyusho	２，４，６↓−トリ↓−０↓−アセチル↓−３↓−デオキシ↓−ヘキソノ↓−１，５↓−ラクトンの製造方法
JP2544609B2 (ja)	1986-10-07	1996-10-16	和光純薬工業株式会社	Ｔｃｎｑ錯体
US4863957A (en)	1987-12-21	1989-09-05	Rorer Pharmaceutical Corporation	Novel HMG-CoA reductase inhibitors
CA1327013C (en)	1988-06-23	1994-02-15	Peter Rex Brawn	Cosmetic composition
CA1334969C (en)	1988-08-19	1995-03-28	Mark James Suto	Substituted dihydroisoquinoline and phthalazine derivatives as potentiators of the lethal effects of radiation and certain chemotherapeutic agents, selected compounds, analogs andprocess
DE59105613D1 (de)	1990-08-24	1995-07-06	Spirig Ag	Verfahren zur Herstellung von Pellets.
JPH04253974A (ja)	1991-02-05	1992-09-09	Ishihara Sangyo Kaisha Ltd	スルホニル尿素系化合物、それらの製造方法及びそれらを含有する除草剤
EP0517969A1 (en)	1991-06-10	1992-12-16	AUSIMONT S.p.A.	Process for increasing the bleaching efficiency of an inorganic persalt or of hydrogen peroxide
US5149838A (en)	1991-09-20	1992-09-22	Merck & Co., Inc.	Intermediates for substituted azetidinones useful as anti-inflammatory and antidegenerative agents
US5610294A (en)	1991-10-11	1997-03-11	The Du Pont Merck Pharmaceutical Company	Substituted cyclic carbonyls and derivatives thereof useful as retroviral protease inhibitors
ZA927272B (en)	1991-10-29	1994-03-23	Du Pont	Herbicidal triazolecarboxamides
GB9208161D0 (en)	1992-04-14	1992-05-27	Pfizer Ltd	Indoles
US5334225A (en)	1992-07-15	1994-08-02	Kao Corporation	Keratinous fiber dye composition containing a 2-substituted amino-5-alkylphenol derivative coupler
US5731292A (en)	1992-11-12	1998-03-24	Tanabe Seiyaku Co., Ltd.	Dihydrochalcone derivatives which are hypoglycemic agents
CA2102591C (en)	1992-11-12	2000-12-26	Kenji Tsujihara	Hypoglycemic agent
DE4243279A1 (de)	1992-12-21	1994-06-23	Bayer Ag	Substituierte Triole
US6297363B1 (en)	1993-02-12	2001-10-02	Nomura Co., Ltd.	Glycoside indoles
JPH06256354A (ja)	1993-03-01	1994-09-13	Nippon Nohyaku Co Ltd	新規テトラゾール化合物及びその製法
JP3187611B2 (ja)	1993-05-17	2001-07-11	キヤノン株式会社	液晶性化合物、これを含む液晶組成物、それを有する液晶素子、それらを用いた表示方法および表示装置
JPH07242526A (ja)	1994-03-03	1995-09-19	Sogo Yatsukou Kk	化粧料
US5830873A (en)	1994-05-11	1998-11-03	Tanabe Seiyaku Co., Ltd.	Propiophenone derivative and a process for preparing the same
EP0732921A4 (en)	1994-09-30	1998-09-02	Ohio State Res Found	C-GLYCOSIDANOLOGIST OF N- (4-HYDROXYPHENYL) RETINAMIDE-O-GLUCURONIDE
US5780483A (en)	1995-02-17	1998-07-14	Smithkline Beecham Corporation	IL-8 receptor antagonists
WO1997025033A1 (en)	1995-10-31	1997-07-17	Eli Lilly And Company	Antithrombotic diamines
JP3059088B2 (ja)	1995-11-07	2000-07-04	田辺製薬株式会社	プロピオフェノン誘導体およびその製法
US5723495A (en)	1995-11-16	1998-03-03	The University Of North Carolina At Chapel Hill	Benzamidoxime prodrugs as antipneumocystic agents
JPH09263549A (ja)	1996-01-25	1997-10-07	Fujisawa Pharmaceut Co Ltd	ベンゼン誘導体の製造法
IL121525A0 (en)	1996-08-26	1998-02-08	Tanabe Seiyaku Co	Process for preparing optically active benzothiazepine compound and intermediate therefor
TW406086B (en)	1996-12-26	2000-09-21	Tanabe Seiyaku Co	Propiophenone derivatives and process for preparing the same
US6153632A (en)	1997-02-24	2000-11-28	Rieveley; Robert B.	Method and composition for the treatment of diabetes
WO1998042347A1 (en)	1997-03-25	1998-10-01	Takeda Chemical Industries, Ltd.	Pharmaceutical composition containing a phosphorylamide and an ayntibiotic
AU736951C (en)	1998-03-19	2003-02-20	Bristol-Myers Squibb Company	Biphasic controlled release delivery system for high solubility pharmaceuticals and method
US6479661B1 (en)	1998-06-18	2002-11-12	Merck Patent Gesellschaft	Method for symmetrically and asymmetrically disubstituting carboxylic acid amides with organotitanates and grignard reagents
FR2780403B3 (fr)	1998-06-24	2000-07-21	Sanofi Sa	Nouvelle forme de l'irbesartan, procedes pour obtenir ladite forme et compositions pharmaceutiques en contenant
JP2000034239A (ja)	1998-07-16	2000-02-02	Asahi Glass Co Ltd	トリフルオロメチル化芳香族化合物の製造方法
JP3857429B2 (ja)	1998-07-17	2006-12-13	ポーラ化成工業株式会社	含硫黄抗真菌剤
US6069238A (en)	1998-09-30	2000-05-30	Eli Lilly And Company	Spirocyclic C-glycosides
US6479531B1 (en)	1998-11-09	2002-11-12	James Black Foundation Limited	Gastrin and cholecystokinin receptor ligands
NZ511614A (en)	1998-11-12	2003-12-19	Smithkline Beecham P	Modified release pharmaceutical composition containing the insulin sensitiser 5-[4-[2-(N-methyl-N-(2- pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione and the antidiabetic agent metaformin
US20020032164A1 (en)	1998-12-30	2002-03-14	Dale Roderic M. K.	Antimicrobial compounds and methods for their use
GB9912961D0 (en)	1999-06-03	1999-08-04	Pfizer Ltd	Metalloprotease inhibitors
PH12000002657B1 (en)	1999-10-12	2006-02-21	Bristol Myers Squibb Co	C-aryl glucoside SGLT2 inhibitors
US6515117B2 (en)	1999-10-12	2003-02-04	Bristol-Myers Squibb Company	C-aryl glucoside SGLT2 inhibitors and method
ATE390140T1 (de)	1999-11-03	2008-04-15	Bristol Myers Squibb Co	Arzneimittel, umfassend eine kombination aus metformin und glibenclamide
JP3450810B2 (ja)	2000-01-31	2003-09-29	キヤノン株式会社	脂肪族ポリエステル、脂肪族ポリエステルの製造方法およびセルロースの再資源化方法
US6627611B2 (en)	2000-02-02	2003-09-30	Kotobuki Pharmaceutical Co Ltd	C-glycosides and preparation of thereof as antidiabetic agents
JP4456768B2 (ja)	2000-02-02	2010-04-28	壽製薬株式会社	Ｃ−配糖体を含有する薬剤
CA2401697A1 (en)	2000-03-03	2001-09-07	Pfizer Products Inc.	Pyrazole ether derivatives as anti-inflammatory/analgesic agents
CN1177857C (zh)	2000-03-17	2004-12-01	橘生药品工业株式会社	吡喃葡萄糖氧基苄基苯衍生物、包含该物质的药用组合物及制备该衍生物用的中间体
US6683056B2 (en)	2000-03-30	2004-01-27	Bristol-Myers Squibb Company	O-aryl glucoside SGLT2 inhibitors and method
US6555519B2 (en)	2000-03-30	2003-04-29	Bristol-Myers Squibb Company	O-glucosylated benzamide SGLT2 inhibitors and method
GB0011098D0 (en)	2000-05-08	2000-06-28	Black James Foundation	Pharmaceutical compositions comprising protpn pump inhibitors and gastrin/cholecystokinin receptor ligands
EP1172362A1 (de)	2000-07-11	2002-01-16	Basf Aktiengesellschaft	Azadioxacycloalkene und ihre Verwendung zur Bekämpfung von Schadpilzen und tierischen Schädlingen
KR100426030B1 (ko)	2000-07-22	2004-04-03	(주) 한켐	락톤계 당화합물에서의 키랄성 전환방법
US6784167B2 (en)	2000-09-29	2004-08-31	Bayer Pharmaceuticals Corporation	17-beta-hydroxysteroid dehydrogenase-II inhibitors
ATE455785T1 (de)	2000-11-02	2010-02-15	Ajinomoto Kk	Neue pyrazolderivate und diese enthaltende mittel gegen diabetes
JP2002167430A (ja)	2000-12-01	2002-06-11	Canon Inc	脂肪族ポリエステル、脂肪族ポリエステルの製造方法およびデンプンの資源化方法
US6476352B2 (en)	2000-12-18	2002-11-05	General Electric Company	Laser beam stop sensor and method for automatically detecting the presence of laser beam stop material using a laser beam stop sensor
CZ305971B6 (cs)	2000-12-28	2016-06-01	Kissei Pharmaceutical Co., Ltd.	Deriváty glukopyranosyloxypyrazolu a jejich použití v léčivech
WO2002068439A1 (fr)	2001-02-26	2002-09-06	Kissei Pharmaceutical Co., Ltd.	Derives de glycopyranosyloxypyrazole et utilisation medicinale de ceux-ci
US7294618B2 (en)	2001-02-27	2007-11-13	Kissei Pharmaceutical Co., Ltd.	Glucopyranosyloxypyrazole derivatives and medicinal use thereof
EP1363954B1 (en)	2001-03-02	2012-10-17	University of Western Ontario	Polymer precursors of radiolabeled compounds, and methods of making and using the same
US6936590B2 (en)	2001-03-13	2005-08-30	Bristol Myers Squibb Company	C-aryl glucoside SGLT2 inhibitors and method
ES2258141T3 (es)	2001-04-11	2006-08-16	Bristol-Myers Squibb Company	Complejos de aminoacidos de glucosidos c-arilo para el tratamiento de la diabetes y procedimiento.
EP1389621A4 (en)	2001-04-27	2005-05-11	Ajinomoto Kk	N-SUBSTITUTED PYRAZOLYL-O-GLYCOSIDE DERIVATIVES AND DIABETES CONTAINING THEREOF
GB0112122D0 (en)	2001-05-18	2001-07-11	Lilly Co Eli	Heteroaryloxy 3-substituted propanamines
US7105556B2 (en)	2001-05-30	2006-09-12	Bristol-Myers Squibb Company	Conformationally constrained analogs useful as antidiabetic and antiobesity agents and method
BR0210510A (pt)	2001-06-20	2005-01-11	Kissei Pharmaceutical	Derivado heterocìclico contendo nitrogênio, composição medicinal contendo o mesmo, uso médico do mesmo e intermediário para o mesmo
WO2003011880A1 (fr)	2001-07-31	2003-02-13	Kissei Pharmaceutical Co., Ltd.	Derive de glucopyranosyloxybenzylbenzene, composition medicinale contenant ce derive, usage medicinal de cette composition et produit intermediaire pour produire cette composition
US20030191121A1 (en)	2001-08-09	2003-10-09	Miller Ross A.	Piperazine carboxamide intermediates of HIV protease inhibitors and processes for their preparation
US20030087843A1 (en)	2001-09-05	2003-05-08	Washburn William N.	O-pyrazole glucoside SGLT2 inhibitors and method of use
US7384763B2 (en)	2001-10-24	2008-06-10	Michael Burton	Method of detecting β-D-ribofuranosidase activity
NZ532478A (en) *	2001-11-08	2007-02-23	Sepracor Inc	Methods for treating depression and other CNS disorders using enantiomerically enriched desmethyl- and didesmethyl-metabolites of citalopram
DE60212683T2 (de)	2001-11-16	2007-06-28	Cutanix Corp., Los Altos	Pharmazeutische und kosmetische zusammensetzungen mit oxy-gruppen-tragenden aromatischen aldehyden
JP2003238417A (ja)	2002-02-18	2003-08-27	Nippon Shoyaku Kenkyusho:Kk	フロレチン配糖体の安定化組成物、該安定化組成物を含有する糖尿病予防・治療剤、および保健食品
US6617313B1 (en)	2002-03-13	2003-09-09	Council Of Scientific And Industrial Research	Glucopyranoside and process of isolation thereof from pterocarpus marsupium pharmaceutical composition containing the same and use thereof
US6562791B1 (en)	2002-03-29	2003-05-13	Council Of Scientific And Industrial Research	Glucopyranoside, process for isolation thereof, pharmaceutical composition containing same and use thereof
HK1080470B (zh)	2002-04-18	2008-03-07	Astrazeneca Ab	杂环化合物
JP2003313168A (ja)	2002-04-18	2003-11-06	Kirin Brewery Co Ltd	Ｂｃｌ−２阻害活性を有する化合物およびその化合物のスクリーニング方法
DE10231370B4 (de)	2002-07-11	2006-04-06	Sanofi-Aventis Deutschland Gmbh	Thiophenglycosidderivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zur Herstellung dieser Arzneimittel
TWI254635B (en)	2002-08-05	2006-05-11	Yamanouchi Pharma Co Ltd	Azulene derivative and salt thereof
NZ535229A (en)	2002-08-09	2006-05-26	Taisho Pharmaceutical Co Ltd	Aryl 5-thio-beta-D-glucopyranoside derivatives and therapeutic agents for diabetes containing the same
WO2004019958A1 (ja)	2002-08-27	2004-03-11	Kissei Pharmaceutical Co., Ltd.	ピラゾール誘導体、それを含有する医薬組成物及びその医薬用途
CA2501239A1 (en)	2002-10-07	2004-04-22	Encore Pharmaceuticals, Inc.	R-nsaid esters and their use
DE10258007B4 (de) *	2002-12-12	2006-02-09	Sanofi-Aventis Deutschland Gmbh	Aromatische Fluorglycosidderivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zur Herstellung dieser Arzneimittel
DE10258008B4 (de)	2002-12-12	2006-02-02	Sanofi-Aventis Deutschland Gmbh	Heterocyclische Fluorglycosidderivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zur Herstellung dieser Arzneimittel
CN100391963C (zh)	2003-01-03	2008-06-04	布里斯托尔-迈尔斯斯奎布公司	制备c-芳基葡糖苷sglt2抑制剂的方法
EP1597266A4 (en)	2003-02-27	2008-02-20	Bristol Myers Squibb Co	NON-CRYOGENIC PROCESS FOR THE PRODUCTION OF GLYCOSIDES
RU2317288C3 (ru)	2003-03-14	2021-03-10	Астеллас Фарма Инк.	С-гликозидные производные и их соли
JP2004300102A (ja)	2003-03-31	2004-10-28	Kissei Pharmaceut Co Ltd	縮合複素環誘導体、それを含有する医薬組成物およびその医薬用途
AU2003902263A0 (en)	2003-05-12	2003-05-29	Fujisawa Pharmaceutical Co., Ltd.	Monosaccharide compounds
JP4708187B2 (ja)	2003-06-20	2011-06-22	キッセイ薬品工業株式会社	ピラゾール誘導体、それを含有する医薬組成物及びその製造中間体
WO2005009539A2 (en)	2003-07-23	2005-02-03	Synta Pharmaceuticals, Corp.	Compounds for inflammation and immune-related uses
UA86042C2 (en)	2003-08-01	2009-03-25	Янссен Фармацевтика Н.В.	Substituted indazole-o-glucosides
SG130189A1 (en)	2003-08-01	2007-03-20	Janssen Pharmaceutica Nv	Substituted indole-o-glucosides
WO2005012318A2 (en)	2003-08-01	2005-02-10	Janssen Pharmaceutica Nv	Substituted fused heterocyclic c-glycosides
WO2005012242A2 (en)	2003-08-01	2005-02-10	Janssen Pharmaceutica Nv	Substituted benzimidazole-, benztriazole-, and benzimidazolone-o-glucosides
WO2005011592A2 (en)	2003-08-01	2005-02-10	Janssen Pharmaceutica N.V.	Substituted indazole-o-glucosides
KR100942622B1 (ko)	2003-08-01	2010-02-17	미쓰비시 타나베 파마 코퍼레이션	나트륨-의존성 수송체에 대해 저해 활성을 갖는 신규화합물
WO2005058845A2 (en)	2003-12-19	2005-06-30	Novo Nordisk A/S	Novel glucagon antagonists/inverse agonists
EP2295422A3 (de)	2004-03-16	2012-01-04	Boehringer Ingelheim International GmbH	Glucopyranosylsubstituierte Benzolderivate, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
US7393836B2 (en)	2004-07-06	2008-07-01	Boehringer Ingelheim International Gmbh	D-xylopyranosyl-substituted phenyl derivatives, medicaments containing such compounds, their use and process for their manufacture
EP1773800A1 (de)	2004-07-27	2007-04-18	Boehringer Ingelheim International GmbH	D-glucopyranosyl-phenyl-substituierte cyclen, diese verbindungen enthaltende arzneimittel, deren verwendung und verfahren zu ihrer herstellung
WO2006018150A1 (de)	2004-08-11	2006-02-23	Boehringer Ingelheim International Gmbh	D-xylopyranosyl-phenyl-substituierte cyclen, diese verbindungen enthaltende arzneimittel, deren verwendung und verfahren zu ihrer herstellung
TW200637839A (en)	2005-01-07	2006-11-01	Taisho Pharmaceutical Co Ltd	1-thio-d-glucitol derivatives
US20090124702A1 (en)	2005-01-25	2009-05-14	Pechetti Siva Satya Krishna Babu	Pharmaceutical Compositions of Metformin
AR053329A1 (es)	2005-01-31	2007-05-02	Tanabe Seiyaku Co	Derivados de indol utiles como inhibidores de los transportadores de glucosa dependientes del sodio (sglt)
CA2595257A1 (en)	2005-02-23	2006-08-31	Boehringer Ingelheim International Gmbh	Glucopyranosyl-substituted ((hetero)arylethynyl-benzyl)-benzene derivatives and use thereof as sodium-dependent glucose cotransporter 2 (sglt2) inhibitors
EP1874787B1 (en)	2005-04-15	2009-12-30	Boehringer Ingelheim International GmbH	Glucopyranosyl-substituted (heteroaryloxy-benzyl)-benzene derivatives as sglt inhibitors
US7772191B2 (en)	2005-05-10	2010-08-10	Boehringer Ingelheim International Gmbh	Processes for preparing of glucopyranosyl-substituted benzyl-benzene derivatives and intermediates therein
JP5128474B2 (ja)	2005-07-27	2013-01-23	ベーリンガーインゲルハイムインターナショナルゲゼルシャフトミットベシュレンクテルハフツング	グルコピラノシル−置換（（ヘテロ）シクロアルキルエチニル−ベンジル）−ベンゼン誘導体、該化合物を含有する薬剤、それらの使用及びそれらの製造方法
WO2007025943A2 (en)	2005-08-30	2007-03-08	Boehringer Ingelheim International Gmbh	Glucopyranosyl-substituted benzyl-benzene derivatives, medicaments containing such compounds, their use and process for their manufacture
AR056195A1 (es)	2005-09-15	2007-09-26	Boehringer Ingelheim Int	Procedimientos para preparar derivados de (etinil-bencil)-benceno sustituidos de glucopiranosilo y compuestos intermedios de los mismos
WO2007087441A2 (en)	2006-01-25	2007-08-02	Synta Pharmaceuticals Corp.	Substituted aromatic compounds for inflammation and immune-related uses
JP2007230999A (ja)	2006-01-31	2007-09-13	Kyoto Univ	置換芳香族ニトリル化合物およびその製造方法
TWI418556B (zh)	2006-07-27	2013-12-11	Mitsubishi Tanabe Pharma Corp	吲哚衍生物
EP2054426A1 (en)	2006-08-15	2009-05-06	Boehringer Ingelheim International GmbH	Glucopyranosyl-substituted cyclopropylbenzene derivatives, pharmaceutical compositions containing such compounds, their use as sglt inhibitors and process for their manufacture
JP5372759B2 (ja)	2006-09-21	2013-12-18	ベーリンガーインゲルハイムインターナショナルゲゼルシャフトミットベシュレンクテルハフツング	グルコピラノシル−置換ジフルオロベンジル−ベンゼン誘導体、該化合物を含有する医薬品及びその使用と調製方法
CA2668623A1 (en)	2006-11-06	2008-05-15	Boehringer Ingelheim International Gmbh	Glucopyranosyl-substituted benzyl-benzonitrile derivatives, medicaments containing such compounds, their use and process for their manufacture
AU2007316613B2 (en)	2006-11-09	2013-11-28	Boehringer Ingelheim International Gmbh	Combination therapy with SGLT-2 inhibitors and their pharmaceutical compositions
UY30730A1 (es)	2006-12-04	2008-07-03	Mitsubishi Tanabe Pharma Corp	Forma cristalina del hemihidrato de 1-(b (beta)-d-glucopiranosil) -4-metil-3-[5-(4-fluorofenil) -2-tienilmetil]benceno
JP5298025B2 (ja)	2006-12-04	2013-09-25	ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ	抗糖尿病薬としてのチエニル含有グリコピラノシル誘導体
EP1956023A1 (en)	2007-02-06	2008-08-13	Lonza Ag	Method for lithium exchange reactions
TW200904405A (en)	2007-03-22	2009-02-01	Bristol Myers Squibb Co	Pharmaceutical formulations containing an SGLT2 inhibitor
US20090047514A1 (en)	2007-08-15	2009-02-19	Allen David P	Thermal Activated Pressure Sensitive Adhesive and Method for Producing the Same and Product therewith
PE20090603A1 (es)	2007-08-16	2009-06-11	Boehringer Ingelheim Int	Composicion farmaceutica que comprende un inhibidor de sglt2 y un inhibidor de dpp iv
LT2187742T (lt)	2007-08-23	2018-01-10	Theracos Sub, Llc	(2s,3r,4r,5s,6r)-2-(4-chlor-3-benzilfenil)-6-(hidroksimetil)tetrahidro-2h-piran-3,4,5-triolio dariniai, skirti panaudoti diabeto gydymui
EP2200606B1 (en)	2007-09-10	2017-10-25	Janssen Pharmaceutica, N.V.	Process for the preparation of compounds useful as inhibitors of sglt
CL2008003653A1 (es)	2008-01-17	2010-03-05	Mitsubishi Tanabe Pharma Corp	Uso de un inhibidor de sglt derivado de glucopiranosilo y un inhibidor de dppiv seleccionado para tratar la diabetes; y composicion farmaceutica.
PE20091730A1 (es)	2008-04-03	2009-12-10	Boehringer Ingelheim Int	Formulaciones que comprenden un inhibidor de dpp4
US9056850B2 (en) *	2008-10-17	2015-06-16	Janssen Pharmaceutica N.V.	Process for the preparation of compounds useful as inhibitors of SGLT
US20110009347A1 (en)	2009-07-08	2011-01-13	Yin Liang	Combination therapy for the treatment of diabetes
NZ599306A (en)	2009-10-14	2014-06-27	Janssen Pharmaceutica Nv	Process for the preparation of compounds useful as inhibitors of sglt2
CA2799204C (en)	2010-05-11	2018-11-06	Janssen Pharmaceutica Nv	Pharmaceutical formulations comprising 1 - (beta-d-glucopyranosyl) - 2 -thienylmethylbenzene derivatives as inhibitors of sglt

2009
- 2009-10-14 US US12/578,934 patent/US9056850B2/en active Active
- 2009-10-15 EP EP12156035.3A patent/EP2455374B1/en active Active
- 2009-10-15 PT PT121560353T patent/PT2455374T/pt unknown
- 2009-10-15 SI SI200932112T patent/SI2455374T1/sl unknown
- 2009-10-15 RS RS20130121A patent/RS52740B/en unknown
- 2009-10-15 WO PCT/EP2009/063503 patent/WO2010043682A2/en active Application Filing
- 2009-10-15 JP JP2011531489A patent/JP6123111B2/ja active Active
- 2009-10-15 PL PL09736928T patent/PL2346888T3/pl unknown
- 2009-10-15 CN CN2009801516486A patent/CN102264714A/zh active Pending
- 2009-10-15 HU HUE12156035A patent/HUE052432T2/hu unknown
- 2009-10-15 HR HRP20130254AT patent/HRP20130254T1/hr unknown
- 2009-10-15 HU HUE12156039A patent/HUE030868T2/en unknown
- 2009-10-15 PL PL12156035T patent/PL2455374T3/pl unknown
- 2009-10-15 CN CN201510944228.0A patent/CN105541814A/zh active Pending
- 2009-10-15 CA CA2946212A patent/CA2946212C/en active Active
- 2009-10-15 SI SI200930548T patent/SI2346888T1/sl unknown
- 2009-10-15 UA UAA201106134A patent/UA107450C2/uk unknown
- 2009-10-15 DK DK09736928.4T patent/DK2346888T3/da active
- 2009-10-15 MX MX2011004054A patent/MX2011004054A/es active IP Right Grant
- 2009-10-15 DK DK12156035.3T patent/DK2455374T3/da active
- 2009-10-15 SI SI200931615A patent/SI2457908T1/sl unknown
- 2009-10-15 EP EP12156039.5A patent/EP2457908B8/en active Active
- 2009-10-15 KR KR1020117010834A patent/KR101724598B1/ko active Active
- 2009-10-15 LT LTEP12156039.5T patent/LT2457908T/lt unknown
- 2009-10-15 LT LTEP12156035.3T patent/LT2455374T/lt unknown
- 2009-10-15 EP EP09736928A patent/EP2346888B1/en active Active
- 2009-10-15 RS RS20170048A patent/RS55577B1/sr unknown
- 2009-10-15 ES ES12156039.5T patent/ES2611881T3/es active Active
- 2009-10-15 CA CA2740853A patent/CA2740853C/en active Active
- 2009-10-15 KR KR1020167017935A patent/KR101679593B1/ko active Active
- 2009-10-15 AU AU2009305413A patent/AU2009305413B2/en active Active
- 2009-10-15 ES ES09736928T patent/ES2399959T3/es active Active
- 2009-10-15 RS RS20210150A patent/RS61484B1/sr unknown
- 2009-10-15 CN CN201310358939.0A patent/CN103467439B/zh active Active
- 2009-10-15 DK DK12156039.5T patent/DK2457908T3/en active
- 2009-10-15 PT PT121560395T patent/PT2457908T/pt unknown
- 2009-10-15 SM SM20170092T patent/SMT201700092T1/it unknown
- 2009-10-15 NZ NZ592204A patent/NZ592204A/xx unknown
- 2009-10-15 ES ES12156035T patent/ES2854598T3/es active Active
- 2009-10-15 SM SM20210072T patent/SMT202100072T1/it unknown
- 2009-10-15 PL PL12156039T patent/PL2457908T3/pl unknown
- 2009-10-15 EA EA201170579A patent/EA021373B1/ru unknown
- 2009-10-15 BR BRPI0920356-7A patent/BRPI0920356B1/pt active IP Right Grant
- 2009-10-15 PT PT97369284T patent/PT2346888E/pt unknown
- 2009-10-16 TW TW098135070A patent/TWI588143B/zh active
- 2009-10-16 TW TW104122678A patent/TW201613905A/zh unknown
- 2009-10-16 TW TW103123880A patent/TWI636981B/zh active
- 2009-10-16 AR ARP090103994A patent/AR073892A1/es active IP Right Grant
2011
- 2011-04-12 IL IL212270A patent/IL212270A0/en unknown
- 2011-04-15 CL CL2011000849A patent/CL2011000849A1/es unknown
- 2011-05-16 ZA ZA2011/03587A patent/ZA201103587B/en unknown
2013
- 2013-03-29 CY CY20131100267T patent/CY1113867T1/el unknown
- 2013-06-05 SM SM201300058T patent/SMT201300058B/xx unknown
2014
- 2014-06-17 JP JP2014124295A patent/JP5905926B2/ja active Active
2015
- 2015-06-10 IL IL239313A patent/IL239313A/en active IP Right Grant
2016
- 2016-03-09 JP JP2016045328A patent/JP2016117758A/ja active Pending
- 2016-11-01 HK HK16112527.9A patent/HK1224289A1/zh unknown
2017
- 2017-02-10 SM SM201700092T patent/SMT201700092B/it unknown
- 2017-02-17 HR HRP20170255TT patent/HRP20170255T1/hr unknown
- 2017-02-21 CY CY20171100236T patent/CY1118708T1/el unknown
2021
- 2021-02-09 HR HRP20210225TT patent/HRP20210225T1/hr unknown
- 2021-02-15 CY CY20211100125T patent/CY1123817T1/el unknown

Also Published As

Publication number	Publication date
TW201443033A (zh)	2014-11-16
KR101679593B1 (ko)	2016-11-25
NZ592204A (en)	2012-12-21
DK2457908T3 (en)	2017-02-13
SI2346888T1 (sl)	2013-05-31
AU2009305413A1 (en)	2010-04-22
BRPI0920356B1 (pt)	2021-09-21
AU2009305413B2 (en)	2015-07-09
US20100099883A1 (en)	2010-04-22
CY1113867T1 (el)	2016-07-27
CN103467439A (zh)	2013-12-25
TWI588143B (zh)	2017-06-21
ES2854598T3 (es)	2021-09-22
EP2455374A1 (en)	2012-05-23
IL239313A0 (en)	2015-07-30
RS61484B1 (sr)	2021-03-31
TW201613905A (en)	2016-04-16
UA107450C2 (uk)	2015-01-12
WO2010043682A3 (en)	2011-08-11
ES2611881T3 (es)	2017-05-11
HRP20170255T1 (hr)	2017-04-07
EA201170579A1 (ru)	2011-10-31
MX2011004054A (es)	2011-05-24
IL212270A0 (en)	2011-07-31
EP2455374B1 (en)	2020-12-16
TW201026689A (en)	2010-07-16
CA2946212C (en)	2018-05-22
EA021373B1 (ru)	2015-06-30
CA2740853C (en)	2017-07-11
CA2740853A1 (en)	2010-04-22
US9056850B2 (en)	2015-06-16
EP2457908A1 (en)	2012-05-30
RS55577B1 (sr)	2017-05-31
CN103467439B (zh)	2016-11-23
JP6123111B2 (ja)	2017-05-10
RS52740B (en)	2013-08-30
PT2346888E (pt)	2013-02-27
EP2457908B1 (en)	2016-11-23
AR073892A1 (es)	2010-12-09
PT2457908T (pt)	2017-03-02
CL2011000849A1 (es)	2011-08-05
JP2012505858A (ja)	2012-03-08
LT2457908T (lt)	2017-03-10
IL239313A (en)	2017-07-31
PT2455374T (pt)	2021-01-20
PL2346888T3 (pl)	2013-06-28
LT2455374T (lt)	2021-05-10
CN105541814A (zh)	2016-05-04
SI2455374T1 (sl)	2021-04-30
JP5905926B2 (ja)	2016-04-20
TWI636981B (zh)	2018-10-01
CA2946212A1 (en)	2010-04-22
CY1123817T1 (el)	2022-05-27
HRP20130254T1 (en)	2013-06-30
CN102264714A (zh)	2011-11-30
KR101724598B1 (ko)	2017-04-07
EP2457908B8 (en)	2017-04-05
PL2457908T3 (pl)	2017-08-31
SMT201700092T1 (it)	2017-03-08
CY1118708T1 (el)	2017-07-12
ES2399959T3 (es)	2013-04-04
SMT201300058B (it)	2013-07-09
HRP20210225T1 (hr)	2021-04-02
HUE052432T2 (hu)	2021-04-28
JP2014167030A (ja)	2014-09-11
PL2455374T3 (pl)	2021-07-12
JP2016117758A (ja)	2016-06-30
HUE030868T2 (en)	2017-06-28
SMT201700092B (it)	2017-03-08
HK1224289A1 (zh)	2017-08-18
WO2010043682A2 (en)	2010-04-22
EP2346888A2 (en)	2011-07-27
SMT202100072T1 (it)	2021-03-15
DK2346888T3 (da)	2013-03-25
DK2455374T3 (da)	2021-02-08
KR20110086039A (ko)	2011-07-27
ZA201103587B (en)	2012-10-31
EP2346888B1 (en)	2013-01-02
KR20160083144A (ko)	2016-07-11
SI2457908T1 (sl)	2017-05-31

Publication	Publication Date	Title
BRPI0920356A2 (pt)	2015-08-04	Processo para a preparação de compostos úteis como inibidores de sglt
BRPI0816258A2 (pt)	2017-05-02	processo para a preparação de compostos úteis como inibidores de sglt
BRPI0911254A2 (pt)	2015-10-06	processo para a preparação de um composto
BRPI0916609A2 (pt)	2015-08-04	Processo para a preparação de um macrociclo
BRPI0819659A2 (pt)	2015-05-26	Processo para produção de álcool
BRPI0910916A2 (pt)	2015-07-28	Processo para a produção de um dianidroaçúcar
BR112012014490A2 (pt)	2015-09-15	processo para a preparação substituída de 1-o-acil-2-desóxi-2-fluoro-4-tio-beta-d-arabinofuranoses
BRPI0807626A2 (pt)	2014-11-25	Processo para a síntese de compostos de 2-aminotiazol como inibidores de quinase
BRPI1013561A2 (pt)	2015-08-25	Processo para a preparação de alogliptina
BRPI0915572A2 (pt)	2017-06-27	processo para a fabricação de epicloroidrina
BRPI0816911A2 (pt)	2015-03-17	Processo para preparação de 4-aminobut-2-enolidas
BRPI0922490A2 (pt)	2015-08-04	Método para produção de beta-santaleno
BRPI0909004A2 (pt)	2015-09-01	Processo para produção de biogás
BRPI0911897A2 (pt)	2015-07-28	Processo para a preparação de compostos, e, composto
BRPI0909393A2 (pt)	2015-12-22	processo para a preparação de polibutadieno
BRPI0921420A2 (pt)	2016-01-05	processo para preparar compostos
BRPI1013830A2 (pt)	2010-10-28	Processo para a iodação de compostos aromáticos
BRPI0813960A2 (pt)	2015-01-06	Processo para produção de biarilas
BR112012002500A2 (pt)	2018-03-13	Processo para o preparo de derivados de ácido 1- (2-halobifenil-4-yl) - ciclopropanocarboxílico
BRPI0913989A2 (pt)	2015-10-20	processo para preparação de derivados de benzoimidazol-2-il pirirmidina
BRPI0813788A2 (pt)	2014-12-30	Processo para preparação de metacrilato de alila
BR112012009789A2 (pt)	2019-09-24	processo para a produção de um álcool
BRPI0911992A2 (pt)	2015-10-20	processo para preparação de bifenilanilidas substituídas
BRPI1008117A2 (pt)	2015-08-25	Processo para a sintese de cleistantina
BRPI1010571A2 (pt)	2019-09-24	processo para a preparação de um composto útil como um inibidor de tafla.

Legal Events

Date	Code	Title	Description
2018-04-17	B06F	Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
2020-06-23	B07D	Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]	Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.
2020-09-29	B07E	Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
2020-11-03	B06U	Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
2021-03-16	B07A	Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
2021-07-13	B09A	Decision: intention to grant [chapter 9.1 patent gazette]
2021-09-21	B16A	Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]	Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 15/10/2009, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF, QUE DETERMINA A ALTERACAO DO PRAZO DE CONCESSAO.